Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Effect of toll-like receptor 3 agonists on the functionality and metastatic properties of breast cancer cell model.

Alizadeh N, Amiri MM, Salek Moghadam A, Zarnani AH, Saadat F, Safavifar F, Berahmeh A, Khorramizadeh MR.

Iran J Allergy Asthma Immunol. 2013 May 15;12(2):161-7.

2.

Interaction of CpG-oligodeoxynucleotides with Toll like receptor 9 induces apoptosis and modulates metaloproteinase-2 activity in human intestinal epithelium.

Khorramizadeh MR, Hosseinzadeh S, Safavifar F, Saadat F, Aalizadeh N, Falak R, Jadali Z, Pezeshki M.

Iran J Allergy Asthma Immunol. 2007 Sep;6(3):107-14.

3.

[Relationship between LKB1 gene and invasion-related factors of breast cancer cells].

Zhuang ZG, Di GH, Hou YF, Liu G, Luo JM, Shen ZZ, Shao ZM.

Zhonghua Yi Xue Za Zhi. 2007 Jan 9;87(2):81-4. Chinese.

PMID:
17418010
4.

Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion.

Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, Shen H, Zhu X.

J Exp Clin Cancer Res. 2010 Jul 10;29:92. doi: 10.1186/1756-9966-29-92.

5.

Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.

Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM.

Breast Cancer Res. 2007;9(6):R76.

6.
7.

Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells.

Chuang JH, Chuang HC, Huang CC, Wu CL, Du YY, Kung ML, Chen CH, Chen SC, Tai MH.

J Biomed Sci. 2011 Aug 23;18:65. doi: 10.1186/1423-0127-18-65.

9.

Functionally active toll-like receptor 3 on human primary and metastatic cancer cells.

Matijevic T, Marjanovic M, Pavelic J.

Scand J Immunol. 2009 Jul;70(1):18-24. doi: 10.1111/j.1365-3083.2009.02262.x.

10.

alpha-Lipoic acid reduces matrix metalloproteinase activity in MDA-MB-231 human breast cancer cells.

Lee HS, Na MH, Kim WK.

Nutr Res. 2010 Jun;30(6):403-9. doi: 10.1016/j.nutres.2010.06.009.

PMID:
20650348
11.

Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.

Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadière C, Chaput N, André F, Kroemer G, Zitvogel L.

Cancer Res. 2010 Jan 15;70(2):490-500. doi: 10.1158/0008-5472.CAN-09-1890. Epub 2010 Jan 12.

12.

Antimetastatic effect and mechanism of ovatodiolide in MDA-MB-231 human breast cancer cells.

Lin KL, Tsai PC, Hsieh CY, Chang LS, Lin SR.

Chem Biol Interact. 2011 Nov 15;194(2-3):148-58. doi: 10.1016/j.cbi.2011.10.002. Epub 2011 Oct 19.

PMID:
22033475
13.

Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway.

Jiang Q, Wei H, Tian Z.

BMC Cancer. 2008 Jan 17;8:12. doi: 10.1186/1471-2407-8-12.

15.

Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells.

Thangapazham RL, Passi N, Maheshwari RK.

Cancer Biol Ther. 2007 Dec;6(12):1938-43. Epub 2007 Sep 1.

PMID:
18059161
16.

CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity.

Montgomery N, Hill A, McFarlane S, Neisen J, O'Grady A, Conlon S, Jirstrom K, Kay EW, Waugh DJ.

Breast Cancer Res. 2012 May 23;14(3):R84.

18.

Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis.

Li DQ, Hou YF, Wu J, Chen Y, Lu JS, Di GH, Ou ZL, Shen ZZ, Ding J, Shao ZM.

Eur J Cancer. 2006 Dec;42(18):3274-86. Epub 2006 Sep 18.

PMID:
16979889
19.

Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.

Brüning A, Friese K, Burges A, Mylonas I.

Breast Cancer Res. 2010;12(4):R45. doi: 10.1186/bcr2602. Epub 2010 Jul 1.

20.

Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor.

Paquette B, Therriault H, Desmarais G, Wagner R, Royer R, Bujold R.

Br J Cancer. 2011 Aug 9;105(4):534-41. doi: 10.1038/bjc.2011.260. Epub 2011 Jul 26.

Supplemental Content

Support Center